Centessa Pharmaceuticals ( (CNTA) ) has shared an update.
Centessa Pharmaceuticals is making strides with its OX2R agonist program, showcasing promising interim data for ORX750 in treating sleep disorders like narcolepsy and hypersomnia. The company is advancing its pipeline with Phase 2a studies and new candidates like ORX142 and ORX489, while reallocating resources from discontinued projects like SerpinPC. With a strong financial position, Centessa is poised to drive innovation and address unmet needs in the neurological and psychiatric treatment landscape.
For a thorough assessment of CNTA stock, go to TipRanks’ Stock Analysis page.
